Quintiles Recognized as Phase I Services Leader for Third Consecutive Year
For the third year in a row, Quintiles has been named the industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) 2015 CRO Quality Benchmarking – Phase I Service Providers report. Quintiles also was identified as the most preferred Phase I service provider based on ISR’s survey of biopharmaceutical industry decision-makers across North America, Europe and Asia.
“We are honored to be recognized once again as the industry leader in Phase I services and most preferred Phase I service provider in ISR’s 2015 report,” said Mary Westrick, Ph.D., vice president, Early Clinical Development at Quintiles. “I believe that the scientific expertise and clinical experience of Quintiles’ staff, as well as our ability to offer integrated solutions, helps our customers make better decisions during early clinical development.”
Survey respondents also identified Quintiles as the “best service provider for differentiation” based on service quality, with particular strengths in data quality, financial strength/stability, and local market/regulatory knowledge.
“I believe the ISR report reflects the effectiveness of our approach to proactive quality management as well as the importance of our unwavering commitment to the highest quality standards,” said Westrick. “Our approach combines Failure Mode and Effects Analysis (FMEA) as well as quality audit findings to identify potential risks early and implement mitigation measures before studies even begin.”
A pioneer in early clinical development approaches, Quintiles helps the biopharmaceutical industry design and deliver standard safety studies as well as complex, multi-site and patient-focused early clinical trials. Leveraging expertise across its global enterprise, Quintiles delivers accurate data and precise insights that inform strategic go/no-go decisions early.
The results of this Phase I study follow Quintiles’ recent recognition in another ISR report that noted the company was once again the industry leader and preferred provider in Phase IV services – a designation it also received for the third consecutive year.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com .
Click here to subscribe to Mobile Alerts for Quintiles.
Phil Bridges, Media Relations, firstname.lastname@example.org
+1-919-998-1653 (office) +1-919-457-6347 (mobile)
Todd Kasper, Investor Relations, InvestorRelations@quintiles.com
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
WA-AVALARA-INC19.6.2018 23:22 | pressemeddelelse
Avalara Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
UNILEVER19.6.2018 19:44 | pressemeddelelse
Unilever Calls on Content Creators and Distributors to Eradicate Stereotypes
AZ-UNIVERSAL-LASER19.6.2018 14:07 | pressemeddelelse
Universal Laser Systems Expands Its Materials Database with Henkel, Hexcel and Saint-Gobain Materials
NY-VALENCE-GROUP19.6.2018 13:59 | pressemeddelelse
Valence Advises Itaúsa on Sale of Brazilian Chemical Co Elekeiroz to H.I.G. Capital
CA-DOLE-FOOD-COMPANY19.6.2018 12:02 | pressemeddelelse
Dole Adds Industry Veteran Michael Solomon as President of Dole Fresh Vegetables
ENAMINE19.6.2018 10:10 | pressemeddelelse
Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum